NCT00302380View on ClinicalTrials.gov

An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
RADIATION

PET imaging using C-11 altropane as the ligand.

A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Massachusetts General Hospital

OTHER

NCT00302380 - An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD | Biotech Hunter | Biotech Hunter